Valuation Metrics and Market Context
As of 3 September 2026, Colinz Laboratories trades at ₹69.61, down 4.38% on the day from a previous close of ₹72.80. The stock’s 52-week range spans ₹36.11 to ₹87.91, indicating significant volatility over the past year. Despite the recent dip, the company’s year-to-date return stands at a robust 29.8%, outperforming the Sensex’s negative 10.15% return over the same period. Over longer horizons, Colinz has delivered exceptional gains, with a 5-year return of 304.71% and a 10-year return of 393.34%, dwarfing the Sensex’s respective 32.35% and 168.37% gains.
However, the recent downgrade in the company’s Mojo Grade from Hold to Sell on 19 June 2026, with a current Mojo Score of 41.0, signals caution. The micro-cap classification further underscores the stock’s higher risk profile relative to larger pharmaceutical peers.
Price-to-Earnings and Price-to-Book Value Analysis
Colinz Laboratories’ P/E ratio currently stands at 34.49, a level that has contributed to its reclassification from expensive to fair valuation. While this multiple remains elevated compared to traditional benchmarks, it is notably lower than several peers in the Pharmaceuticals & Biotechnology sector. For instance, Ind-Swift Laboratories and Fredun Pharma trade at P/E ratios of 48.09 and 56.23 respectively, both classified as very expensive or expensive. Similarly, Shukra Pharmaceuticals and Jagsonpal Pharma exhibit P/E ratios exceeding 33, reinforcing Colinz’s relative valuation appeal.
The company’s P/BV ratio of 1.74 also supports the fair valuation grade. This figure suggests that the stock is trading at a modest premium to its book value, which is reasonable given its return on capital employed (ROCE) of 12.08% and return on equity (ROE) of 5.04%. These profitability metrics, while moderate, indicate operational efficiency and shareholder value creation that justify a valuation above book value but below the high premiums seen in some peers.
Enterprise Value Multiples and Growth Considerations
Enterprise value (EV) multiples provide further insight into Colinz’s valuation. The EV to EBIT and EV to EBITDA ratios both stand at 9.31, while EV to capital employed is 4.89 and EV to sales is 1.60. These multiples are comparatively conservative when juxtaposed with sector heavyweights, suggesting that the market is pricing in moderate growth expectations and risk factors.
The PEG ratio of 0.37 is particularly noteworthy, indicating that the stock’s price-to-earnings multiple is low relative to its earnings growth rate. This metric often signals undervaluation and potential for price appreciation if growth trends continue. However, investors should weigh this against the company’s modest ROE and the broader sector dynamics.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Comparative Valuation within the Pharmaceuticals Sector
When benchmarked against peers, Colinz Laboratories’ valuation appears more attractive. Several competitors are classified as very expensive, including Ind-Swift Labs (P/E 48.09, EV/EBITDA 46.14), Shukra Pharma (P/E 60.53, EV/EBITDA 42.13), and Hester Biosciences (P/E 34.99, EV/EBITDA 23.61). Even Fredun Pharma, with a P/E of 56.23 and EV/EBITDA of 23.7, commands a premium valuation.
Conversely, Venus Remedies and TTK Healthcare are rated fair and attractive respectively, with Venus at a P/E of 18.93 and TTK Healthcare at 20.65. This spectrum of valuations highlights the diverse investor sentiment and growth prospects within the sector. Colinz’s position in the fair valuation category suggests a middle ground, balancing growth potential with risk considerations.
Recent Price Performance and Market Sentiment
Colinz Laboratories has experienced a notable correction in recent weeks, with a one-month return of -15.11% compared to the Sensex’s -1.95%. The one-week decline of 4.00% also outpaces the benchmark’s 1.17% fall. These short-term setbacks may reflect profit-taking or sector rotation pressures, but the stock’s longer-term performance remains impressive.
The company’s strong 1-year return of 60.47% and 3-year return of 66.53% underscore its resilience and growth trajectory. These figures suggest that despite recent volatility, Colinz has delivered substantial shareholder value over time, outperforming the broader market by a wide margin.
Colinz Laboratories Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investment Implications and Outlook
The shift in Colinz Laboratories’ valuation grade from expensive to fair reflects a recalibration of investor expectations amid evolving financial metrics and sector dynamics. The company’s P/E and P/BV ratios, while still elevated relative to some peers, have moderated sufficiently to enhance price attractiveness.
Investors should consider the company’s solid ROCE of 12.08%, which indicates efficient capital utilisation, alongside a modest ROE of 5.04%. The low PEG ratio of 0.37 suggests that earnings growth is not fully priced in, potentially offering upside if growth sustains. However, the micro-cap status and recent negative price momentum warrant caution, particularly for risk-averse investors.
Comparative analysis within the Pharmaceuticals & Biotechnology sector reveals that Colinz Laboratories occupies a valuation sweet spot between expensive and attractive peers. This positioning may appeal to investors seeking exposure to the sector without the premium multiples associated with larger or more speculative companies.
Overall, while the downgrade to a Sell grade signals prudence, the company’s long-term performance and fair valuation metrics suggest that selective investors with a higher risk tolerance might find value in the stock at current levels. Continuous monitoring of earnings growth, sector trends, and broader market conditions will be essential to reassess the investment thesis going forward.
Summary of Key Financial Metrics
Colinz Laboratories Ltd currently trades at:
- P/E Ratio: 34.49 (Fair valuation)
- Price to Book Value: 1.74
- EV to EBIT/EBITDA: 9.31
- EV to Capital Employed: 4.89
- EV to Sales: 1.60
- PEG Ratio: 0.37
- ROCE: 12.08%
- ROE: 5.04%
These figures position the company as fairly valued relative to its sector peers, with potential for re-rating should growth accelerate or profitability improve.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
